Investigational deuterated psilocybin analog, CYB003, reduced major depressive disorder symptoms by 14 points on the Montgomery-Asberg Depression Rating Scale by day 21 in a phase II study, said developer Cybin.
Jazz Pharmaceuticals halted a phase I trial of JZP441 — an investigational sleep disorder treatment — due to adverse events like cardiovascular effects and visual disturbances. (FierceBiotech)
Firearm suicides in the U.S. reached an “unprecedented high” in 2022, a CDC report found. (Morbidity and Mortality Weekly Report)
Specific auricular acupuncture over 6 weeks was safe but not more effective for depression recovery than nonspecific auricular acupuncture after 3 months in a randomized trial. (JAMA Network Open)
Traumatic memories appeared to have their own neural pathways, which may explain why they can be vivid and intrusive. (Nature Neuroscience)
Magnetic seizure therapy performed just as well as ultrabrief pulse right unilateral electroconvulsive therapy and had fewer adverse effects when treating a major depressive episode. (JAMA Psychiatry)
Workers at the Sutter Center for Psychiatry in Sacramento, California, plan to strike today over poor working conditions. (Becker’s Hospital Review)
Researchers developed a novel screening tool — the Hospital Mental Health Risk Screen — to help predict mental health outcomes for hospitalized trauma patients. (Journal of the American College of Surgeons)
More early negative life events, a thicker orbitofrontal cortex at the age of 14, and accelerated orbitofrontal cortex thinning throughout adolescence predicted young adults’ depressive symptoms. (JCPP Advances)
The Senate health care committee will consider a sweeping bill next week designed to fight the opioid epidemic, sources told STAT.
Bilateral high-frequency repetitive transcranial magnetic stimulation helped improve negative symptoms of schizophrenia, as well as event-based prospective memory. It didn’t help time-based prospective memory, though. (Neuropsychopharmacology Reports)